Hybrid coronary revascularization: present indications and future perspective

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology

Background:

• Hybrid coronary revascularization (HCR) integrates left internal mammary artery (LIMA) bypass grafting to the left anterior descending (LAD) artery with percutaneous coronary intervention (PCI) for other lesions.
• This strategy leverages the benefits of LIMA-LAD grafts and drug-eluting stents (DES) for non-LAD regions.
• HCR is typically reserved for high-risk patients with specific coronary anatomy.

Purpose of the Study:

• To evaluate the safety and efficacy of the HCR strategy.
• To assess outcomes such as mortality, morbidity, and resource utilization in patients undergoing HCR.

Main Methods:

• Review of small, non-randomized studies examining HCR outcomes.
• Comparison of HCR with conventional coronary artery bypass grafting (CABG) in selected patient populations.

Main Results:

• HCR demonstrates low mortality and morbidity rates.
• Patients undergoing HCR experience shorter intensive care unit and hospital stays.
• Despite a lack of large randomized trials, existing data suggest favorable outcomes.

Conclusions:

• HCR is a safe and promising alternative to CABG for select patients with multivessel coronary artery disease.
• The approach appears cost-effective, offering potential benefits in terms of recovery time.
• Further multicenter randomized trials are warranted to solidify HCR's role in treatment guidelines.